BridgeBio Pharma Inc (NASDAQ: BBIO) is 28.39% higher on its value in year-to-date trading and has touched a low of $21.62 and a high of $39.47 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BBIO stock was last observed hovering at around $34.18 in the last trading session, with the day’s gains setting it 1.05%.
Currently trading at $35.23, the stock is 4.40% and 4.13% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.83 million and changing 3.07% at the moment leaves the stock 21.71% off its SMA200. BBIO registered 42.40% gain for a year compared to 6-month gain of 35.40%. The firm has a 50-day simple moving average (SMA 50) of $33.7623 and a 200-day simple moving average (SMA200) of $28.8984.
The stock witnessed a -5.35% loss in the last 1 month and extending the period to 3 months gives it a -1.70%, and is 2.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.31% over the week and 5.92% over the month.
BridgeBio Pharma Inc (BBIO) has around 730 employees, a market worth around $6.49B and $221.90M in sales. Profit margin for the company is -241.44%. Distance from 52-week low is 62.95% and -10.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.67%).
with sales reaching $57.27M over the same period.The EPS is expected to shrink by -28.21% this year, but quarterly earnings will post 5.50% year-over-year. Quarterly sales are estimated to shrink -72.87% in year-over-year returns.
359.0 institutions hold shares in BridgeBio Pharma Inc (BBIO), with institutional investors hold 97.35% of the company’s shares. The shares outstanding are 190.04M, and float is at 155.16M with Short Float at 13.99%. Institutions hold 92.01% of the Float.
The top institutional shareholder in the company is KOHLBERG KRAVIS ROBERTS & CO. L.P. with over 31.06 million shares valued at $786.77 million. The investor’s holdings represent 16.5582 of the BBIO Shares outstanding. As of 2024-06-30, the second largest holder is VIKING GLOBAL INVESTORS LP with 25.12 million shares valued at $636.31 million to account for 13.3917 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 14.05 million shares representing 7.4924 and valued at over $356.01 million, while BLACKROCK INC. holds 6.636 of the shares totaling 12.45 million with a market value of $315.31 million.
BridgeBio Pharma Inc (BBIO) Insider Activity
The most recent transaction is an insider sale by Ellis Andrea, the company’s Director. SEC filings show that Ellis Andrea sold 10,000 shares of the company’s common stock on Apr 14 ’25 at a price of $35.00 per share for a total of $0.35 million. Following the sale, the insider now owns 12000.0 shares.
Still, SEC filings show that on Apr 01 ’25, Ellis Andrea (Director) disposed off 30,000 shares at an average price of $34.05 for $1.02 million. The insider now directly holds 12,000 shares of BridgeBio Pharma Inc (BBIO).
